Why the study?
Does an elevated NTproBNP level (>331 ng/L) predict adverse clinical outcomes in patients with NSTEMI/UA?
Does an elevated NTproBNP level (>331 ng/L) predict adverse clinical outcomes in patients with NSTEMI/UA?
Answers are grounded in this paper and cite their sources.
NTproBNP >331 ng/L provides independent prognostic value for 1-year adverse outcomes in patients with NSTEMI/UA, offering incremental predictive power over traditional risk markers.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2011 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: